Xiamen Amoytop Biotech Hits Day High with Strong 4.31% Intraday Surge

Xiamen Amoytop Biotech Co. has seen a notable increase of 4.31% on August 10, 2026, reaching an intraday high of CNY 60.27. This performance stands out against the backdrop of the China Shanghai Composite, which gained only 0.67% on the same day. Despite the recent uptick, Xiamen Amoytop's one-week performance shows a slight decline of 0.21%, while its one-month performance reflects a modest increase of 4.79%. However, the stock has faced challenges over the past year, with a significant drop of 31.33%, contrasting sharply with the China Shanghai Composite's gain of 9.12%. Financially, the company has reported impressive metrics, including net sales of CNY 1,216.02 million and an operating profit of CNY 472.2 million, marking the highest figures in recent quarters. With a return on equity of 34.50% and a price-to-book ratio of 12.11, Xiamen Amoytop maintains a fair valuation. The company has also consistently delivered positive results for the last 18 consecutive quarters, indicating a stable operational performance.